• 13 Dec 17

  New Data Supporting Use Of Anagrelide To Treat Cancer

  ( 409.6 KB)
• 12 Dec 17

  Appendix 3B amended

  ( 928.0 KB)
• 12 Dec 17

  Change of Director’s Interest Notice

  ( 374.6 KB)
• 12 Dec 17

  Appendix 3B

  ( 555.7 KB)
• 06 Dec 17

  SUDA Licensee Submits Marketing Authorisation

  ( 398.0 KB)
• 29 Nov 17

  Change of Company Name

  ( 233.8 KB)
• 28 Nov 17

  Appointment of David Phillips as Advisor to the Board

  ( 372.5 KB)
• 28 Nov 17

  Results of Meeting

  ( 411.8 KB)
• 28 Nov 17

  AGM presentation

  ( 2.1 MB)
• 28 Nov 17

  SUDA Acquires Novel Oro-Mucosal Anti-Cancer Agent

  ( 390.8 KB)